Huge Underuse of Germline Testing for Cancer Patients

Rates of germline genetic testing for patients newly diagnosed with common cancers are far below recommended levels, prompting calls for innovative solutions.

Related Keywords

California ,United States ,Ann Arbor ,Michigan ,New York ,Memorial Sloan Kettering Cancer Center ,Stanford ,Georgia ,Chicago ,Illinois ,Stanford University ,American ,Deborah Schrag ,Alison Kurian ,Erin Frances Cobain ,Daiichi Sankyo ,Zsofiak Stadler ,Genedx Bioreference ,Novartis ,Regeneron Pharmaceuticals ,National Comprehensive Cancer Network ,Ayala Pharmaceuticals ,National Institutes Of Health ,Stanford University School Of Medicine ,American Society Of Clinical Oncology ,Journal Of The American Medical Association ,Centers For Disease ,Optos Plc ,Department Of Medicine ,Astrazeneca ,University Of Michigan Health ,Genentech ,End Results ,Stanford University School ,American Society ,Clinical Oncology ,American Medical ,New York City ,Michigan Health ,Hispanic White ,National Institutes ,Disease Control ,Ambry Genetics ,Color Genomics ,Adverum Biotechnologies ,Outlook Therapeutics ,Genomics ,Genomic Medicine ,Edicine Genomic ,Breast Cancer ,Alignant Breast Neoplasm ,Cancer ,Alignant Neoplasia ,Arcinoma ,Ovarian Cancer ,Alignant Ovarian Neoplasm ,Biologic Therapy ,Targeted Therapy ,Coronavirus ,019 Novel Coronavirus ,019 Ncov ,Uhan Coronavirus ,Uman Coronavirus Hku1 ,Uman Coronavirus Oc43 ,Cov Oc43 ,Uman Coronavirus 229e ,Cov 229e ,Lung Cancer ,Ung Carcinoma ,Dancer ,